Lexeo Therapeutics(LXEO) - 2025 Q2 - Quarterly Results

Lexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational Highlights Breakthrough Therapy designation granted for LX2006 based on interim data from Phase I/II trials demonstrating clinically meaningful improvements in cardiac and neurologic measures of Friedreich ataxia Exhibit 99.1 LX2006 selected for FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot (CDRP) program, created to facilitate CMC registrational readiness and support faster patient access Eight par ...